Literature DB >> 21847759

Develope monoclonal antibody against foot-and-mouth disease virus A type.

Tong Lin1, Jing Li, Jun-jun Shao, Guo-zheng Cong, Jun-zheng Du, Shan-dian Gao, Hui-yun Chang.   

Abstract

In order to develop an anti-FMDV A Type monoclonal antibody (mAb), BABL/c mice were immunized with FMDV A type. Monoclonal antibodies (mAbs) 7B11 and 8H4 against Foot-and-mouth disease virus (FMDV) serotype A were produced by fusing SP2/0 myeloma cells with splenocyte from the mouse immunized with A/AV88. The microneutralization titer of the mAbs 7B11 and 8H4 were 1024 and 512, respectively. Both mAbs contain kappa light chains, the mAbs were IgG1. In order to define the mAbs binding epitopes, the reactivity of these mAbs against A Type FMDV, were examined using indirect ELISA, the result showed that both mAbs reacted with A Type FMDV. These mAbs may be used for further vaccine studies, diagnostic methods, prophylaxis, etiological and immunological research on FMDV. Characterization of these ncindicated that prepared anti-FMDV A mAbs had no cross-reactivity with Swine Vesicular Disease (SVD) or FMDV O, Asia1 and C Type antigens. Their titers in abdomen liquor were 1:5×10(6) and 1:2×10(6), respectively. 7B11 was found to be of subtype IgG(1), 8H4 was classified as IgG(2b) subtype. The mAbs prepared in this study, are specific for detection of FMDV serotype A, and is potentially useful for pen-side diagnosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847759      PMCID: PMC8222452          DOI: 10.1007/s12250-011-3199-4

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  9 in total

1.  Type-independent detection of foot-and-mouth disease virus by monoclonal antibodies that bind to amino-terminal residues of capsid protein VP2.

Authors:  B Freiberg; B Höhlich; B Haas; A Saalmüller; E Pfaff; O Marquardt
Journal:  J Virol Methods       Date:  2001-04       Impact factor: 2.014

2.  Generating fusions to glutathione S-transferase for protein studies.

Authors:  D B Smith
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

Review 3.  Structure and receptor binding.

Authors:  Terry Jackson; Andrew M Q King; Dave I Stuart; Elizabeth Fry
Journal:  Virus Res       Date:  2003-01       Impact factor: 3.303

4.  Human glutaredoxin 2 affinity tag for recombinant peptide and protein purification.

Authors:  Mathias Lundberg; Arne Holmgren; Magnus Johansson
Journal:  Protein Expr Purif       Date:  2005-07-27       Impact factor: 1.650

Review 5.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Authors:  M Feldmann; R N Maini
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

6.  Cloning and expression of human rotavirus spike protein, VP8*, in Escherichia coli.

Authors:  J Kovacs-Nolan; E Sasaki; D Yoo; Y Mine
Journal:  Biochem Biophys Res Commun       Date:  2001-04-20       Impact factor: 3.575

7.  Immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus O/China99.

Authors:  Huichen Guo; Zaixin Liu; Shiqi Sun; Huifang Bao; Yingli Chen; Xiangtao Liu; Qingge Xie
Journal:  Vaccine       Date:  2005-05-09       Impact factor: 3.641

8.  Radial immuno-diffusion and serum-neutralisation techniques for the assay of antibodies to swine vesicular disease.

Authors:  S M Golding; R S Hedger; P Talbot
Journal:  Res Vet Sci       Date:  1976-03       Impact factor: 2.534

9.  Genetic characterisation of the recent foot-and-mouth disease virus subtype A/IRN/2005.

Authors:  Joern Klein; Manzoor Hussain; Munir Ahmad; Preben Normann; Muhammad Afzal; Soren Alexandersen
Journal:  Virol J       Date:  2007-11-15       Impact factor: 4.099

  9 in total
  1 in total

1.  Development of Monoclonal Antibody Specific to Foot-and-Mouth Disease Virus Type A for Serodiagnosis.

Authors:  Quyen Thi Nguyen; Jihyun Yang; Jae-Won Byun; Hyun Mi Pyo; Mi-Young Park; Bok Kyung Ku; Jinju Nah; Soyoon Ryoo; Sung-Hwan Wee; Kang-Seuk Choi; Haryoung Poo
Journal:  Pathogens       Date:  2019-12-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.